Investors Urged to Take Action as Deadline Approaches for Regeneron Pharmaceuticals Lawsuit

Attention Regeneron Investors!

A critical deadline is fast approaching for investors of Regeneron Pharmaceuticals, Inc. who may have suffered significant losses. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims on behalf of those who purchased or acquired Regeneron securities between November 2, 2023, and October 30, 2024. The law firm is calling upon investors who experienced losses exceeding $100,000 to reach out and discuss their options.

Understanding the Allegations

The investigation revolves around allegations that Regeneron, along with its executives, may have violated federal securities laws. Specifically, the complaint suggests that the company engaged in misleading statements and failed to disclose crucial information that could impact investor decisions. The issues raised include:
1. Regeneron's practice of paying credit card fees to distributors under the condition of not raising credit card charges to Eylea customers.
2. This arrangement allegedly subsidized customer prices when using credit cards for purchases, creating an artificial boost in reported Eylea sales.
3. By not declaring these payments as price concessions, Regeneron overstated their Average Selling Price (ASP) reported to federal agencies, which violates the False Claims Act.

Recent Developments

In April 2024, the U.S. Department of Justice (DOJ) filed a complaint against Regeneron under the False Claims Act, asserting that the company had omitted crucial disclosures regarding discounts it provided to drug distributors. A failure to report these discounts is alleged to have inflated the ASP of Regeneron’s blockbuster drug, Eylea, leading to inappropriate increases in Medicare reimbursements. The implications of this revelation led to a plunge in Regeneron’s stock by over 3% within just two trading days.

Later, on October 31, 2024, Regeneron reported disappointing third-quarter financial results, revealing a modest 3% sales increase that fell short of analysts' expectations. This news further contributed to a significant drop in the stock price, which sank by approximately 9% after the announcement.

Your Rights as an Investor

The lead plaintiff in a class action lawsuit is typically the person that has the largest stake in the outcome and is most representative of the class. Shareholders of Regeneron who are considering joining this action have until March 10, 2025, to act and possibly assume the lead role. Even if you opt not to take leading plaintiff responsibilities, you can still benefit from any possible recovery by remaining an absent class member.

The investigation is ongoing, and the firm encourages anyone with additional information regarding Regeneron’s potential wrongful conduct—be it conveyances from whistleblowers, former employees, or shareholders—to come forward.

If you believe you qualify or if you’re just looking for more information, we strongly advise contacting Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You can also explore more on their website at www.faruqilaw.com/REGN.

This is an important time for Regeneron investors - act swiftly to protect your interests and rights!